Download PDF
CC BY-NC-ND 4.0 · World J Nucl Med 2019; 18(03): 227-231
DOI: 10.4103/wjnm.WJNM_61_18
Review Article

Investigating patients with normocalcemic hyperparathyroidism: When is a parathyroid scintigraphy indicated?

Elias E. Mazokopakis
Department of Internal Medicine, Naval Hospital of Crete, Chania, Greece
,
Spyridon-Nikitas I. Skarakis
Department of Internal Medicine, Naval Hospital of Crete, Chania, Greece
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

In clinical practice, physicians often encounter patients with persistent elevated serum parathyroid hormone levels and normal serum calcium levels, a state known as normocalcemic hyperparathyroidism (NHPT). The investigation of NHPT cases can lead to unnecessary use of parathyroid scintigraphy (PS) and consequently unnecessary health-care costs. In this clinical review, the most common causes of NHPT and the possible indications for PS performance in such cases are mainly presented and discussed.

Keywords

Normocalcemic hyperparathyroidism - parathyroid hormone - parathyroid scintigraphy - primary hyperparathyroidism - secondary hyperparathyroidism - Vitamin D

Financial support and sponsorship

Nil.




Publication History

Received: 21 June 2018

Accepted: 13 July 2018

Article published online:
22 April 2022

© 2019. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Mazokopakis E, Papadomanolaki M, Skarakis SN, Tsekouras K. Primary and secondary hyperparathyroidism among Vitamin D deficient Hashimoto's thyroiditis patients and the need for a parathyroid scan. Hell J Nucl Med 2017;20:258-9.
  • 2 Sanadgol H, Ardalan MR, Tamadon MR, Mardani S, Nasri H. Current concepts on normocalcemic primary hyperparathyroidism. J Parathyr Dis 2013;1:21-3.
  • 3 Cordellat IM. Hyperparathyroidism: Primary or secondary disease? Reumatol Clín. 2012;8:287-91.
  • 4 Martínez Díaz-Guerra G, Jódar Gimeno E, Reyes García R, Gómez Sáez JM, Muñoz-Torres M; Grupo de Trabajo de Metabolismo Mineral y Óseo de la Sociedad Española de Endocrinología y Nutrición. Normocalcemic primary hyperparathyroidism: Recommendations for management and follow-up. Endocrinol Nutr 2013;60:456.e1-6.
  • 5 Souberbielle JC, Cavalier E, Cormier C. How to manage an isolated elevated PTH? Ann Endocrinol (Paris) 2015;76:134-41.
  • 6 Cocchiara G, Fazzotta S, Palumbo VD, Damiano G, Cajozzo M, Maione C, et al. The medical and surgical treatment in secondary and tertiary hyperparathyroidism. Review. Clin Ter 2017;168:e158-67.
  • 7 Reddy P, Edwards LR. Magnesium supplementation in Vitamin D deficiency. Am J Ther 2017. [Epub ahead of print].
  • 8 Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of Vitamin D deficiency: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911-30.
  • 9 World Health Organization Scientific Group on the Prevention and Management of Osteoporosis. Prevention and Management of Osteoporosis: Report of a World Health Organization Scientific Group. Technical Report Series; 921. Geneva: World Health Organization; 2003.
  • 10 Moralidis E. The imaging of parathyroid glands with radionuclides. In: Grammaticos PH. and co., editor. Clinical and Laboratory Nuclear Medicine in 20 Specialties. 5th ed. Thessaloniki: Kyriakidis Broth; 2015. p. 100-9.
  • 11 Wills MR, Pak CY, Hammond WG, Bartter FC. Normocalcemic primary hyperparathyroidism. Am J Med 1969;47:384-91.
  • 12 Díaz-Soto G, Julián MT, Puig-Domingo M. Normocalcemic primary hyperparathyroidism: A newly emerging disease needing therapeutic intervention. Hormones (Athens) 2012;11:390-6.
  • 13 Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism. Arq Bras Endocrinol Metabol 2010;54:106-9.
  • 14 Bilezikian JP, Khan AA, Potts JT Jr. Third International Workshop on the Management of Asymptomatic Primary hyperparathyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the third international workshop. J Clin Endocrinol Metab 2009;94:335-9.
  • 15 Cusano NE, Silverberg SJ, Bilezikian JP. Normocalcemic primary hyperparathyroidism. J Clin Densitom 2013;16:33-9.
  • 16 Greenspan BS, Dillehay G, Intenzo C, Lavely WC, O'Doherty M, Palestro CJ, et al. SNM practice guideline for parathyroid scintigraphy 4.0. J Nucl Med Technol 2012;40:111-8.
  • 17 Alenezi SA, Asa'ad SM, Elgazzar AH. Scintigraphic parathyroid imaging: concepts and new developments. Res Rep Nucl Medi 2015;5:9-18.
  • 18 Chen G, Xue Y, Zhang Q, Xue T, Yao J, Huang H, et al. Is normocalcemic primary hyperparathyroidism harmful or harmless? J Clin Endocrinol Metab 2015;100:2420-4.
  • 19 Vieira JG. PTH assays: Understanding what we have and forecasting what we will have. J Osteoporos 2012;2012:523246.
  • 20 Sadat-Ali M, Al-Omran AS, Al-Turki HA. Parathyroid glands response to low vitamin D levels in healthy adults: A cross-sectional study. Ulster Med J 2015;84:26-9.
  • 21 Berson SA, Yalow RS, Aurbach GD, Potts JT. Immunoassay of bovine and human parathyroid hormone. Proc Natl Acad Sci U S A 1963;49:613-7.
  • 22 Carneiro-Pla D, Solorzano C. A summary of the new phenomenon of normocalcemic hyperparathyroidism and appropriate management. Curr Opin Oncol 2012;24:42-5.
  • 23 Shlapack MA, Rizvi AA. Normocalcemic primary hyperparathyroidism-characteristics and clinical significance of an emerging entity. Am J Med Sci 2012;343:163-6.
  • 24 Harvey A, Hu M, Gupta M, Butler R, Mitchell J, Berber E, et al. Anew, vitamin D-based, multidimensional nomogram for the diagnosis of primary hyperparathyroidism. Endocr Pract 2012;18:124-31.
  • 25 Rajhbeharrysingh U, El Youssef J, Leon E, Lasarev MR, Klein R, Vanek C, et al. Expanding the net: The re-evaluation of the multidimensional nomogram calculating the upper limit of normal PTH (maxPTH) in the setting of secondary hyperparathyroidism and the development of the multIdimensional predictive hyperparaTHyroid model (Mi-PTH). Surgery 2016;159:226-39.
  • 26 Jin J, Mitchell J, Shin J, Berber E, Siperstein AE, Milas M. Calculating an individual maxPTH to aid diagnosis of normocalemic primary hyperparathyroidism. Surgery 2012;152:1184-92.